Jade Biosciences, Inc. Common Stock JBIO Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$40.37M-26.4% | -$31.93M-26.8% | -$25.18M+21.7% | -$32.13M+15.8% | -$38.17M+18.8% | ||
| $9K0.0% | $9K-25.0% | $12K+1,100% | $1K-75.0% | $4K-50.0% | ||
| $7.41M-21.2% | $9.4M+119% | $4.3M+10.3% | $3.9M+60.8% | $2.42M+92.9% | ||
| $2.33M+673% | $301K— | —— | $2.26M-15.5% | $2.68M+108% | ||
| $5.77M— | —— | $4.58M-4.8% | $4.81M+347% | -$1.95M-149% | ||
| —— | —— | $1.86M+6,739% | -$28K+53.3% | -$60K— | ||
| -$29K— | —— | —— | —— | $9K— | ||
| -$24.08M+28.4% | -$33.65M-52.1% | -$22.12M-9.7% | -$20.16M-7.5% | -$18.76M+17.1% | ||
| —— | $3K-94.7% | $57K-56.5% | $131K+2,520% | $5K— | ||
| $73.9M-34.4% | $112.6M— | —— | —— | —— | ||
| $65.43M— | —— | —— | —— | $12.85M-2.1% | ||
| -$8.47M+91.4% | -$98.16M+34.0% | -$148.71M-1,045% | -$12.99M-201% | $12.85M-2.1% | ||
| $45K+105% | $22K0.0% | $22K0.0% | $22K0.0% | $22K-92.8% | ||
| -$795K-100% | $170.16M— | $0-100% | $191.31M+27,430% | -$700K-101% | ||
| -$7K+58.8% | -$17K— | —— | —— | —— | ||
| -$33.35M-187% | $38.33M+122% | -$170.84M-200% | $171.01M+979% | -$19.46M-128% | ||
| $493K-19.2% | $610K— | —— | —— | —— | ||
| —— | $0— | $0-100% | $6.18M-59.8% | $15.4M+22.2% | ||
| $9K0.0% | $9K-25.0% | $12K+1,100% | $1K-75.0% | $4K-50.0% | ||
| -$4.18M— | —— | -$332K+92.7% | -$4.53M-422% | $1.41M-74.4% | ||
| $5.77M— | —— | $4.58M-4.8% | $4.81M+347% | -$1.95M-149% | ||
| -$29K— | —— | —— | —— | $9K— | ||
| -$5.44M-153% | $10.2M+2,369% | $413K-51.5% | $851K+67.9% | $507K+91.3% | ||
| $65.43M+1,716% | $3.6M0.0% | $3.6M0.0% | $3.6M0.0% | $3.6M— | ||
| —— | —— | —— | —— | $700K-76.7% | ||
| —— | —— | —— | $11K+120% | $5K— | ||
| —— | $5000.0% | $5000.0% | $5000.0% | $500— | ||
| —— | —— | —— | —— | $1.09M— | ||
| -$7K+58.8% | -$17K— | —— | —— | —— | ||
| -$29K— | —— | —— | —— | $9K— | ||
| —— | $104K0.0% | $104K0.0% | $104K0.0% | $104K— | ||
| —— | $2.79M0.0% | $2.79M0.0% | $2.79M0.0% | $2.79M— | ||
| —— | $210K0.0% | $210K0.0% | $210K0.0% | $210K+44.8% | ||
| $26K0.0% | $26K— | —— | $66K+725% | $8K— | ||
| —— | —— | —— | —— | $773K— | ||
| —— | $255K0.0% | $255K0.0% | $255K0.0% | $255K— | ||
| —— | -$33.65M-51.7% | -$22.18M-9.3% | -$20.29M-8.1% | -$18.76M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Jade Biosciences, Inc. Common Stock generate?
- Jade Biosciences, Inc. Common Stock (JBIO) generated -$100.0M in operating cash flow over the trailing twelve months.
- What is Jade Biosciences, Inc. Common Stock's free cash flow?
- After $196.0K of capital expenditures, Jade Biosciences, Inc. Common Stock's free cash flow was -$94.9M over the trailing twelve months, down 66.7% year over year.
- Where does Jade Biosciences, Inc. Common Stock's cash flow data come from?
- Every line is extracted from Jade Biosciences, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.